Dec 15 (Reuters) - Knight Therapeutics Inc GUD.TO
* The financial terms of agreement were not disclosed
* Knight therapeutics- as per agreement, co will be responsible for all commercial, regulatory, certain supply chain activities for movantik in canada, israel
* Movantik is currently under regulatory review in israel and, when approved, will be marketed under name moventig
* Press release - knight therapeutics announces exclusive license agreement with astrazeneca for movantik/moventig(r) in canada and israel Source text for Eikon: ID:nCCN4VCL2j Further company coverage: GUD.TO